For the first quarter of the fiscal year ending March 2027, consolidated net sales were 71,380 million yen, up 9.6% year over year; operating income was 6,519 million yen, up 25.2% YoY; ordinary income was 7,941 million yen (derivative valuation gains of 1,424 million yen included); net income attributable to owners of the parent for the quarter was 5,531 million yen, marking a substantial increase. The full-year guidance remains unchanged. Both domestic and overseas segments posted higher sales, with overseas growth driven by expansion in Europe. Equity ratio 38.0%; cash and deposits, etc. 41,724 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Toa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4553-20260806-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending March 2027, consolidated net sales were 71,380 million yen, up 9.6% year over year; operating income was 6,519 million yen, up 25.2% YoY; ordinary income was 7,941 million yen (derivative valuation gains of 1,424 million yen included); net income attributable to owners of the parent for the quarter was 5,531 million yen, marking a substantial increase. The full-year guidance remains unchanged. Both domestic and overseas segments posted higher sales, with overseas growth driven by expansion in Europe. Equity ratio 38.0%; cash and deposits, etc. 41,724 million yen.","jir_summary":"### Outlook and Financial Position\nTotal assets stood at 480,709 million yen, with shareholders\u2019 equity ratio at 38.0%, indicating stability. Inventory increases and higher accounts receivable contributed to solid cash flow. A supplemental earnings materials and an earnings briefing are planned, with no revision to earnings forecasts at this time. As measures to stabilize supply in the pharmaceutical industry continue, strengthening production and supply frameworks domestically and internationally has contributed to results.","jir_financial_highlights":"Sales: 71,380\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd49.6\uff05\u5897)\nOperating profit: 6,519\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd425.2\uff05\u5897)\nOrdinary profit: 7,941\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd4100.9\uff05\u5897)\nNet income attributable to owners of the parent for the quarter: 5,531\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd4120.1\uff05\u5897)\nTotal assets: 480,709\u767e\u4e07\u5186 (\u524d\u9023\u7d50\u4f1a\u8a08\u5e74\u5ea6\u672b\u6bd44,?\uff085,418\u767e\u4e07\u5186\u5897\uff09)\nShareholders\u2019 equity ratio: 38.0\uff05 (\u524d\u671f38.0\uff05\u2192\u73fe\u671f38.0\uff05\uff08\u6a2a\u3070\u3044\uff09)","jir_category":"","jir_hashtags":"#ToaPharmaceutical, #EarningsRelease, #DomesticOverseasSegmentGrowth","jir_key_figures":"Sales: 71,380\u767e\u4e07\u5186\uff08\u524d\u5e74\u540c\u671f\u6bd49.6%\u5897\uff09\nOperating profit: 6,519\u767e\u4e07\u5186\uff08\u540c25.2%\u5897\uff09\nNet income attributable to owners of the parent for the quarter: 5,531\u767e\u4e07\u5186\uff08\u540c120.1%\u5897\uff09","jir_meta_title":"Toa Pharmaceutical Q1 FY2027 Financial Results | Net Sales 71,380 million yen (up 9.6% YoY)","jir_meta_description":"Summary of Toa Pharmaceutical's Q1 FY2027 financial results. Highlights of sales, operating profit and net income, segment trends, full-year outlook, and financial position.","jir_og_title":"Toa Pharmaceutical Q1 Results Highlights","jir_og_description":"Toa Pharmaceutical's Q1 FY2027 results show an increase in revenue and profit. Summary of domestic and overseas segment trends and financial position.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-97480","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n